Pardoprunox

Pardoprunox

150px
Systematic (IUPAC) name
7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
Clinical data
Routes of administration	Oral
Legal status
Legal status	Uncontrolled
Identifiers
CAS Number	269718-84-5
ATC code	none
PubChem	CID 6918524
ChemSpider	5293721
Chemical data
Formula	C12H15N3O2
Molar mass	269.73 g/mol[[]]

Pardoprunox (SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson's disease and as of March 2010 is in Phase III clinical trials. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.

Pardoprunox acts as a D₂ (pK_i = 8.1) and D₃ receptor (pK_i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT_1A receptor (pK_i = 8.5) full agonist (IA = 100%). It also binds to D₄ (pK_i = 7.8), α₁-adrenergic (pK_i = 7.8), α₂-adrenergic (pK_i = 7.4), and 5-HT₇ receptors (pK_i = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.

See also

• Aripiprazole
• Bifeprunox

Further reading

• Hauser RA, Bronzova J, Sampaio C; et al. (2009). "Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease". European Neurology. 62 (1): 40–8. doi:10.1159/000216839. PMID 19407454. CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)